Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.46 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 4/20 | 0.50 |
| ▸ | TERT | O14746 | 3/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.46 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | PPARD | Q03181 | 3/20 | 0.46 |
| ▸ | PPARA | Q07869 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | FABP4 | P15090 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20258167 | 1.00 | SLC6A5 (0.51) | SLC6A5FAAHTERTPTPN1PPARG | |
| Hydrochloric Acid SCHEMBL1773161 | 1.00 | SLC6A5 (0.51) | SLC6A5FAAHTERTPTPN1PPARG | |
| Hydrochloric Acid SCHEMBL14060920 | 1.00 | SLC6A5 (0.51) | SLC6A5FAAHTERTPTPN1PPARG | |
| SCHEMBL533830 | 0.99 | SLC6A5 (0.52) | SLC6A5FAAHTERTPTPN1PPARG | |
| SCHEMBL29077348 | 0.99 | SLC6A5 (0.52) | SLC6A5FAAHTERTPTPN1PPARG | |
| SCHEMBL533829 | 0.99 | SLC6A5 (0.52) | SLC6A5FAAHTERTPTPN1PPARG | |
| Bromide SCHEMBL29058708 | 0.97 | SLC6A5 (0.51) | SLC6A5FAAHTERTPTPN1PPARG | |
| Hydrochloric Acid SCHEMBL28566602 | 0.97 | SLC6A5 (0.51) | SLC6A5FAAHTERTPTPN1PPARG | |
| Hydrochloric Acid SCHEMBL17241611 | 0.92 | MAPK1 (0.48) | SLC6A5CYP1A2MAPTCYP2C19BLM | |
| Hydrochloric Acid SCHEMBL1773167 | 0.92 | MAPK1 (0.48) | SLC6A5CYP1A2MAPTCYP2C19BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2319519-B1 | COMPOSITION FOR INHIBITING EXPRESSION OF TARGET GENE | KYOWA HAKKO KIRIN CO LTD (JP) | 2016-01-27 | — | — | EP | claimed |
| US-20150247148-A1 | COMPOSITION FOR SUPPRESSING EXPRESSION OF TARGET GENE | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-09-03 | — | — | US | claimed |
| EP-1842558-B1 | COMPOSITION FOR INHIBITING EXPRESSION OF TARGET GENE | KYOWA HAKKO KIRIN CO LTD (JP) | 2012-06-13 | — | — | EP | claimed |
| US-20110182980-A1 | COMPOSITION FOR SUPPRESSING EXPRESSION OF TARGET GENE | KYOWA KIRIN CO., LTD. (JP) | 2011-07-28 | — | — | US | claimed |
| EP-2319519-A1 | COMPOSITION FOR INHIBITING EXPRESSION OF TARGET GENE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-05-11 | — | — | EP | claimed |
| US-7785623-B2 | Compositions and methods useful for the reduction of fine lines and wrinkles | BIOZONE LABORATORIES, INC. | 2010-08-31 | — | — | US | claimed |
| US-7709457-B2 | treating bladder cancer; transfecting with polynucleotide into urothelial cells; improved transfection efficiency with cationic lipids, cationic polymers or dendrimers; improve drug delivery with a solubilized cholesterol | GENECURE PTE LTD. (SG) | 2010-05-04 | — | — | US | claimed |
| US-20090175930-A1 | Composition Suppressing The Expression of Target Gene in Eyeball and Medicament For Treating of Disease in Eyeball | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-07-09 | — | — | US | claimed |
| US-20090011003-A1 | Composition for Suppressing Expression of Target Gene | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-01-08 | — | — | US | claimed |
| EP-1970078-A1 | COMPOSITION INHIBITING THE EXPRESSION OF TARGET GENE IN EYEBALL AND REMEDY FOR DISEASE IN EYEBALL | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-09-17 | — | — | EP | claimed |
| US-7320963-B2 | Transfecting polynucleotide into cells; obtain transfection mixture, incubate with solublize in cholesterol mixture, expose with cells, recover transfected cells | GENECURE PTE LTD (SG) | 2008-01-22 | — | — | US | claimed |
| EP-1842558-A1 | COMPOSITION FOR INHIBITING EXPRESSION OF TARGET GENE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-10-10 | — | — | EP | claimed |
| WO-2004030654-A1 | COMPOSITIONS AND METHODS USEFUL FOR THE REDUCTION OF FINE LINES AND WRINKLES | KELLER BRIAN C (US) | 2004-04-15 | — | — | WO | claimed |
| US-20040062780-A1 | Compositions and methods useful for the reduction of fine lines and wrinkles | BIOZONE LABORATORIES, INC. | 2004-04-01 | — | — | US | claimed |
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | ASCENDIS PHARMA A/S (DK) | 2026-04-07 | — | — | US | disclosed |
| US-20250387508-A1 | METHODS OF PRODUCING HYDROGEL MICROSPHERES | ASCENDIS PHARMA AS (DK) | 2025-12-25 | — | — | US | disclosed |
| EP-4646231-A1 | DRUG CONJUGATES FOR THE TREATMENT OF OCULAR DISORDERS | Ascendis Pharma Ophthalmology Division A/S (DK) | 2025-11-12 | — | — | EP | disclosed |
| WO-2001078786-A2 | HIGH AFFINITY PEPTIDE-CONTAINING NANOPARTICLES | ALNIS BIOSCIENCES, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
| EP-1025066-A2 | MOLECULAR COMPOUNDS HAVING COMPLEMENTARY SURFACES TO TARGETS | Alnis, LLC (US) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999019276-A2 | MOLECULAR COMPOUNDS HAVING COMPLEMENTARY SURFACES TO TARGETS | ALNIS, LLC (US) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | CD44, H1-0, MMP1 | CHRM1 578/4885SLC6A2 2089/4885SLC6A5 832/4885 |
| US-20250387508-A1 | METHODS OF PRODUCING HYDROGEL MICROSPHERES | CD44, PF4, FGF2 | CHRM1 2859/4885SLC6A2 1275/4885SLC6A5 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.